Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | Chief Legal Officer | November 21, 2025 | November 26, 2025 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Legal Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEKTAR THERAPEUTICS
Report date November 21, 2025 · Filed November 26, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,215 |
Reported balance
After 2025-11-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-11-21 · Grant · Acquired 1,903 · Balance 22,215 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. F3: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 21,585 |
Reported balance
After 2025-11-25 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-11-25 · Sale · Disposed 630 · Balance 21,585 F4: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $281.25 · Expires 2028-12-17 | Direct | 3,400 |
Reported balance
After 2025-11-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-21 · Grant · Acquired 3,400 · Balance 3,400 F6: These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. F7: The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant.
F2: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025.
F3: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c).
F4: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person.
F5: This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
F6: These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant.
F7: The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025.
Septerna, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2036-02-05 | Direct | 165,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 165,000 · Balance 165,000 F1: 25% of the shares underlying this option will vest on January 5, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option will vest on January 5, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2026 Filed Feb 10, 2026 19:01 UTC | Septerna, Inc. SEPN · Entity 2452 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $25.41 | $0.00 |
DisclosureSEC source: 0001193125-26-045086 · ownership.xml · derivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2036-02-05 F1 · derivative.exercise_date: 25% of the shares underlying this option will vest on January 5, 2027, and the remaining 75% of the shares underlying this option will vest in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 01:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 630 | $54.28 | $34,196.40 |
DisclosureSEC source: 0001193125-25-297852 · ownership.xml · nonDerivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,585 F4 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 3,400 | $0.00 Strike: $281.25 | $0.00 |
DisclosureSEC source: 0001193125-25-297852 · ownership.xml · derivative · entry 3 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400 Underlying: Common Stock · 3,400 shares Expires 2028-12-17 F6 · security: These stock options were granted on December 18, 2020 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of four years from the date of grant. F7 · derivative.exercise_date: The Compensation Committee determined on November 20, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on November 21, 2025. Read SEC document |
| November 21, 2025 Filed Nov 26, 2025 01:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 1,903 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-297852 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,215 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 18, 2020 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 20, 2025 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on November 21, 2025. F3 · balance_after: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 21,666 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950170-25-110774 · ownership.xml · derivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,666 Underlying: Common Stock · 21,666 shares Expires 2031-12-12 F5 · security: These stock options were granted on December 13, 2023 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F6 · derivative.exercise_date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined on July 17, 2025 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on August 19, 2025 (subject to remaining time-based vesting requirements). Read SEC document |
| August 19, 2025 Filed Aug 22, 2025 01:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 676 | $26.59 | $17,974.84 |
DisclosureSEC source: 0000950170-25-110774 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,312 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.19 to $27.15 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 508 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). F4 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split. Read SEC document |
| May 19, 2025 Filed May 22, 2025 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 9,996 | $0.67 | $6,697.32 |
DisclosureSEC source: 0000950170-25-075977 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 314,296 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.69 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 23:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 11,040 | $1.01 | $11,150.40 |
DisclosureSEC source: 0000950170-25-025040 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,292 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| December 24, 2024 Filed Dec 27, 2024 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 16,560 | $0.89 | $14,738.40 |
DisclosureSEC source: 0000950170-24-140591 · ownership.xml · nonDerivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,332 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $.89 to $.90 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| December 23, 2024 Filed Dec 27, 2024 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 33,402 | $0.90 | $30,061.80 |
DisclosureSEC source: 0000950170-24-140591 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,892 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $.87 to $.91 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 325,000 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0000950170-24-137544 · ownership.xml · derivative · entry 3 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2032-12-12 F6 · derivative.exercise_date: Stock options vest over four years from the date of grant, (December 13, 2024) in equal monthly installments based on continued service. Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 331,875 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0000950170-24-137544 · ownership.xml · derivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,875 Underlying: Common Stock · 331,875 shares Expires 2030-08-14 F4 · security: These stock options were granted on August 15, 2022 under the 2017 Plan and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a monthly pro-rata basis over a period of three years from the date of grant. F5 · derivative.exercise_date: The Compensation Committee determined on November 18, 2024 that the performance-based vesting requirement for these stock options was satisfied and these stock options vested on December 13, 2024 (subject to remaining time-based vesting requirements). Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:54 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 165,938 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-137544 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 385,294 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on August 15, 2022 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer ("Compensation Committee") determined on November 18, 2024 that the performance-based vesting requirement for these RSUs was satisfied and these RSUs vested on December 13, 2024 (subject to remaining time-based vesting requirements). F3 · balance_after: This number includes 7,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| November 19, 2024 Filed Nov 21, 2024 01:36 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,407 | $1.01 | $6,471.07 |
DisclosureSEC source: 0000950170-24-129462 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,856 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.00 to $1.04. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 6,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 01:15 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,651 | $1.28 | $7,233.28 |
DisclosureSEC source: 0000950170-24-099353 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,263 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.24 to $1.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 6,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| May 17, 2024 Filed May 21, 2024 01:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,260 | $1.75 | $10,955.00 |
DisclosureSEC source: 0000950170-24-062644 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,414 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.72 to $1.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 6,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 01:17 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,606 | $0.68 | $5,172.08 |
DisclosureSEC source: 0000950170-24-019044 · ownership.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,674 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.66 to $0.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 6,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| December 13, 2023 Filed Dec 15, 2023 23:05 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 325,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001209191-23-058860 · doc4.xml · derivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2031-12-12 F1 · derivative.exercise_date: This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 02:00 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,179 | $0.49 | $3,517.71 |
DisclosureSEC source: 0001209191-23-056183 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 243,780 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.47 to $0.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 5,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,221 | $0.78 | $5,632.38 |
DisclosureSEC source: 0001209191-23-046461 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,959 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.75 to $0.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 5,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2023 Filed May 18, 2023 00:28 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 7,543 | $0.72 | $5,430.96 |
DisclosureSEC source: 0001209191-23-030447 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,680 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $0.71 to $0.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 5,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2023 Filed Feb 18, 2023 01:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,275 | $3.00 | $24,825.00 |
DisclosureSEC source: 0001209191-23-010954 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,223 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.94 to $3.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 5,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,690 | $3.57 | $31,023.30 |
DisclosureSEC source: 0001209191-22-057967 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,498 F1 · shares: Represents the number of shares sold by the reporting person to cover required tax withholding obligations in connection with the vesting of the RSUs held by the reporting person and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.42 to $3.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 4,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,189 | $4.76 | $15,179.64 |
DisclosureSEC source: 0001209191-22-046488 · doc4.xml · nonDerivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,188 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $4.67 to $4.88. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F2 · balance_after: This number includes 4,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock · Derivative | 331,875 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001209191-22-046488 · doc4.xml · derivative · entry 3 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,875 Underlying: Common Stock · 331,875 shares Expires 2030-08-14 F5 · security: Stock options were granted in connection with a retention program and the individual's recent promotion. These stock options are in lieu of the Issuer's usual end-of-year annual performance grants. F6 · derivative.exercise_date: Stock options vest over three years from the date of grant in substantially equal monthly installments based on continued service. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 23:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 165,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046488 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,377 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted in connection with a retention program and the individual's recent promotion. This grant is in lieu of Issuer's usual end-of-year annual performance grants. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 4,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2022 Filed May 18, 2022 01:38 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,136 | $3.95 | $12,387.20 |
DisclosureSEC source: 0001209191-22-029904 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,939 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 3,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 23:18 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,661 | $10.95 | $40,087.95 |
DisclosureSEC source: 0001209191-22-011441 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,075 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.77 to $11.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 3,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 67,150 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-21-070695 · doc4.xml · derivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,150 Underlying: Common Stock · 67,150 shares Expires 2029-12-15 F3 · derivative.exercise_date: This stock option vests over four years from the date of grant in equal monthly installments based on continued service. Read SEC document |
| December 16, 2021 Filed Dec 21, 2021 01:27 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 37,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070695 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,736 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock. These RSUs vest over three years from the date of grant in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 3,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2021 Filed Nov 17, 2021 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,564 | $13.16 | $86,382.24 |
DisclosureSEC source: 0001209191-21-065225 · doc4.xml · nonDerivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,436 F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5 · price: This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer. F3 · balance_after: This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| November 15, 2021 Filed Nov 17, 2021 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 20,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-065225 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,000 F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · balance_after: This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under the plan is exempt under Rule 16b-3(c). Read SEC document |
| October 12, 2021 Filed Oct 15, 2021 01:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 35,800 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-21-060512 · doc4.xml · derivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,800 Underlying: Common Stock · 35,800 shares Expires 2027-12-11 F1 · security: These stock options were granted on December 12, 2019 under the Company's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. F2 · date: The Organization and Compensation Committee of the Board of Directors of the Company determined that the performance-based vesting requirement for these stock options was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these stock options vested on the next monthly vesting date (October 12, 2021) following the date that the performance-based vesting requirement was satisfied. F3 · derivative.exercise_date: These stock options vest on a monthly pro-rata basis over a period of four years from the grant date (December 12, 2019). Read SEC document |
| August 16, 2021 Filed Aug 18, 2021 23:02 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,910 | $13.83 | $26,415.30 |
DisclosureSEC source: 0001209191-21-052393 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,900 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.69 to $14.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 17, 2021 Filed May 19, 2021 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,917 | $18.30 | $35,081.10 |
DisclosureSEC source: 0001209191-21-034190 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,810 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:06 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,173 | $22.37 | $48,610.01 |
DisclosureSEC source: 0001209191-21-012124 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,727 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.04 to $22.67. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 3,107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 5,344 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-21-007946 · doc4.xml · derivative · entry 3 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,344 shares Expires 2021-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,344 | $19.45 | $103,940.80 |
DisclosureSEC source: 0001209191-21-007946 · doc4.xml · nonDerivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,900 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.30 to $19.60. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 3,107 shares held by the reporting person in his account under the Issuer's ESPP Plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). Read SEC document |
| February 03, 2021 Filed Feb 5, 2021 01:44 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 5,344 | $8.80 | $47,027.20 |
DisclosureSEC source: 0001209191-21-007946 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · balance_after: This number includes 3,107 shares held by the reporting person in his account under the Issuer's ESPP Plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c). Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:52 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 51,000 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064917 · doc4.xml · derivative · entry 2 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2028-12-17 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:52 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 28,550 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064917 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,900 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 3,107 shares shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,539 | $16.93 | $26,055.27 |
DisclosureSEC source: 0001209191-20-059246 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,850 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.71 to $17.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 2,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:40 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,529 | $19.67 | $30,075.43 |
DisclosureSEC source: 0001209191-20-047619 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,389 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 2,607 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:32 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 1,529 | $22.51 | $34,417.79 |
DisclosureSEC source: 0001209191-20-031017 · doc4.xml · nonDerivative · entry 1 Wilson Mark Andrew · CIK 0001808356 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,418 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.29 to $22.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 2107 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.